

Opioid Misuse in Vermont

The US is in the middle of an opioid epidemic. In 2020, 9.3 million Americans aged 12 years or older reported past-year misuse of prescription pain relievers.ⁱ Preliminary data indicate that opioid-related fatalities among Vermont residents increased from 114 in 2019 to 157 in 2020, and fentanyl now accounts for 88% of all accidental and undetermined opioid-related fatalities.ⁱⁱ


The Opioid Overdose Prevention and Reversal Project (OOPRP) and Vermont's Response

The OOPRP collaborates with community-based organizations to distribute naloxone and provides overdose response training, opioid misuse prevention training, and referrals to treatment across Vermont. As one piece of the State of Vermont's coordinated effort to reduce opioid-related fatalities, the OOPRP works to ensure that first responders and the public are trained in overdose response. The goal of the OOPRP is to distribute naloxone overdose rescue kits to individuals at risk of overdose, family members of those at risk, and anyone who may be able to help in the event of an overdose.


Naloxone Distribution Through OOPRP

The total number of **client visits** to OOPRP sites and **naloxone kits** distributed decreased in 2020. This decrease is likely due to many distribution sites being closed to in person operations because of the COVID-19 pandemic.

Most individuals visiting OOPRP sites are **new clients** (73%). In total, 27% of clients have visited an OOPRP site more than once. Only **161 individuals (2%) have visited 11 or more times** since the program started in 2013. Fewer clients visited OOPRP sites in 2020, and sites distributed less naloxone kits.



Most clients have only visited an OOPRP site once since 2013.



Preliminary Data from Community Naloxone Distribution Sites – 2021

The following tables contain data collected by OOPRP community naloxone distribution sites. These data are updated on a quarterly basis. Historic data may change if there are delays in reporting. All data in the following tables should be considered preliminary until final data are published.

Client Visits and Distribution of Kits – Preliminary 2021 Data*,**								
Q1 Q2 Q3 Q4								
Number of New Clients	175	207	255					
Number of Returning Clients	193	274	299					
Total	368	481	554					
Kits of Naloxone Distributed	1,962	2,697	3,059					

*Clients are classified as new/returning/other using the following criteria: (1) new clients are those receiving naloxone who are filling out a naloxone survey for the first time; (2) returning clients are those receiving naloxone who have filled out a naloxone survey at any point since the start of the naloxone program (December 2013) prior to their visit; and (3) other clients are those not receiving naloxone who are filling out the survey – regardless of whether they have visited an OOPRP site for naloxone in the past or not.

**Quarterly totals will not match yearly totals for distribution data collected from returning clients. For example, if a unique client visits an OOPRP site in 3 out of 4 quarters during the year, they count 3 times toward the total number of unique returning clients if counted by discrete quarters. However, they would only count one time toward the total number of unique returning clients if a count was done for that single year.

Information Reported by Naloxone Kit Recipients – Preliminary 2021 Data*						
	Q1	Q2	Q3	Q4	Total	
Overdoses Reported by Naloxone Kit Recipients	78	79	120		277	
Number of Individuals Administered Naloxone in Response to a Perceived Overdose	74	70	113		257	
Number of Kits Used to Reverse a Perceived Overdose	127	136	210		473	
Successful Overdose Reversals Reported	49	46	81		176	

*This information is reported by individuals who have received a naloxone kit through the OOPRP at any point in time – not just those picking up a naloxone kit at the time of the survey.

As a result of OOPRP community naloxone distribution, since 2014...



47,683 naloxone kits have been distributed.



2,392 lives have been saved.

Naloxone Administration by Emergency Medical Services (EMS) Personnel

Naloxone is administered by EMS personnel when medically indicated in several scenarios, including perceived overdoses and cardiac arrests. These administrations are captured in Vermont's State Incident Reporting Network (SIREN) database.


SIREN data indicate that Vermont EMS agencies administered 780 doses of naloxone to 554 individual patients in 2020 (8 of these incidents occurred out of state, accounting for 14 total administrations of naloxone).

Demographic Breakdown of Individuals Administered Naloxone by EMS (2020)



Source: Vermont State Incident Reporting Network (SIREN), 2020

Addison County had a significantly lower rate of administrations per 10,000 residents in 2020 (3.8). All other counties were statistically similar to Vermont overall.



Rate of EMS calls involving narcan administration per 10,000 residents in county (2020).

Source: Vermont State Incident Reporting Network (SIREN), 2020 Note: Essex and Grand Isle have been suppressed due to insufficient data. *Statistically significant at 0.05 level, compared to Vermont rate (8.8 per 10,000 Vermonters).

Preliminary SIREN Data – 2021

The following tables contain data from the Statewide Incident Reporting Network (SIREN). These data outline the use of naloxone by emergency medical personnel in Vermont. These data are updated on a quarterly basis. Historic data may change if there are delays in reporting. All data in the following tables should be considered preliminary until final data are published. Note - because EMS agencies do not administer a 'standardized' 4mg dose of naloxone, SIREN data are not comparable to those collected by OOPRP sites.

Number of Individual Patients Administered Naloxone via EMS by County of Incident – Preliminary 2021 Data						
	Q1	Q2	Q3	Q4	Total	
Addison	*	*	9		20	
Bennington	11	9	14		34	
Caledonia	*	*	11		21	
Chittenden	31	42	43		116	
Essex	0	0	0		0	
Franklin	10	16	21		47	
Grand Isle	*	*	*		*	
Lamoille	*	*	7		15	
Orange	11	*	*		20	
Orleans	*	13	*		26	
Rutland	13	21	27		61	
Washington	14	14	14		42	
Windham	8	14	27		49	
Windsor	12	19	14		45	
Out of State	*	*	*		9	
Total VT Counties	128	170	201		499	

Number of Individual Patients Administered Naloxone via EMS by Gender and Age, and Number of Doses Received – Preliminary 2021 Data						
	Q1	Q2	Q3	Q4	Total	
Gender						
Male	84	122	139		345	
Female	45	53	63		164	
Age						
< 17	*	*	*		*	
18 - 29	19	35	32		86	
30 - 59	88	110	131		329	
60 +	20	28	37		85	

*Fewer than 6 records - data have been suppressed.

Number of Individual Patients Administered Naloxone via EMS by Number of Doses Received – Preliminary 20201 Data							
Number of Doses Received	Q1 Q2 Q3 Q4 Total						
1	81	118	135		334		
2	40	44	54		138		
3	7	12	13		32		
4	*	*	*		*		

Number of Naloxone Administrations via EMS by Route of Administration – Preliminary 2021 Data						
	Q1	Q2	Q3	Q4	Total	
Intranasal	117	140	178		435	
Intravenous (IV)	44	71	64		179	
Intraosseous (IO)	9	9	23		41	
Intramuscular (IM)	7	10	11		28	
Other/Miscellaneous	9	16	14		39	

*Fewer than 6 records – data have been suppressed.

Key Takeaways:

Vermont has been utilizing its resources to bend the curve on the upward trend of opioid overdoses. The OOPRP plays a critical role in addressing the opioid epidemic by targeting services to people who are using drugs, their family members, or others that may be in a position to help in the event of an opioid overdose. The program helps to ensure communities have access to overdose education, training, naloxone rescue kits, and referrals to other services. The training provides guidance on how to prevent, recognize, and respond to an overdose. In addition to reversing overdoses, the OOPRP and EMS agencies across the state are helping to build community networks and employ a comprehensive response to the opioid epidemic.

For more information on the OOPRP: http://www.healthvermont.gov/naloxone

For more information on SIREN: https://www.healthvermont.gov/siren

For data questions: Mallory Staskus, Mallory.staskus@vermont.gov

https://www.samhsa.gov/data/sites/default/files/reports/rpt35325/NSDUHFFRPDFWHTMLFiles2020/202 ONSDUHFFR1PDFW102121.pdf

https://www.healthvermont.gov/sites/default/files/documents/pdf/ADAPOpioidFatalityDataBrief2 020_Final.pdf